Yves A. D'udekem

Yves A. D'udekem

M.D., Ph.D.

Pediatric Cardiologist

38 years of overall experience

Male📍 Parkville

About of Yves A. D'udekem

Yves A. D'udekem is a Pediatric Cardiologist based in Parkville, VIC, working out of Flemington Road, Parkville. He looks after babies, children, and teens with heart conditions that can be present from birth or develop as a child grows.


Over time, he has built a strong practice caring for a wide range of congenital heart disease. That can include problems with how the heart is formed, valve issues, and blood flow conditions that need careful follow-up. At times, kids may also come with heart rhythm concerns or other serious heart problems that affect how well the body is coping.


Parents often want clear answers and a steady plan, especially when things feel complicated. Yves focuses on helping families understand what is happening and what the next steps might be. In many cases, that means ongoing care, monitoring, and making decisions alongside the wider team at the hospital.


He brings 38 years of overall experience to the role. His background includes training that covers both general surgery and cardiothoracic surgery, and then further fellowships in cardiac surgery. He also completed cardiac surgery fellowships at Great Ormond Street Hospital for Children in the UK and at Toronto General Hospital’s Western Division.


For education, he holds an M.D. and Ph.D. He completed his medical degree at Université Catholique de Louvain, starting in 1987, and later added postgraduate training there as well. This strong base helped shape a career that mixes hands-on surgical training with long-term heart care for children.


He also works with published work and keeps up with newer findings, so care stays grounded in evidence rather than guesswork. When suitable, he may be part of discussions around clinical trials, but the main goal is always making sure the right option fits each child’s situation.


If your child has been diagnosed with a heart condition, Yves offers calm, practical guidance through the process—whether that means regular review, managing symptoms, or planning treatment with the team.

Education

  • M.D.; UniversitĂ© Catholique de Louvain; 1987
  • Postgraduate degrees; UniversitĂ© Catholique de Louvain
  • Fellowships - General Surgery & Cardiothoracic Surgery, Cliniques Universitaires Saint-Luc, 1994
  • Fellowships - Cardiac Surgery, Great Ormond Street Hospital for Children NHS Trust, 1999
  • Fellowships - Cardiac Surgery, Toronto General Hospital – Western Division

Services & Conditions Treated

Coarctation of the AortaPulmonary AtresiaTetralogy of FallotTruncus ArteriosusVentricular Septal DefectsAortopulmonary WindowAtrioventricular Septal DefectCongenital Mitral StenosisCongenital TracheomalaciaDouble Inlet Left VentricleHeart Valve RepairHeterotaxy SyndromeHypoplastic Left Heart Syndrome (HLHS)Interrupted Aortic ArchTotal Anomalous Pulmonary Venous ReturnTransposition of the Great ArteriesTricuspid AtresiaAortic RegurgitationBronchitisCongenital Aneurysms of the Great VesselsCongenital Cardiovascular ShuntCongenital Coronary Artery MalformationCongenital Heart Disease (CHD)Heart TransplantHigh Blood Pressure in InfantsMitral StenosisPulmonary Atresia with Intact Ventricular SeptumPulmonary Valve StenosisPulmonary Veno-Occlusive DiseaseAberrant Subclavian ArteryAnomalous Left Coronary Artery from the Pulmonary ArteryAortic Valve StenosisArrhythmiasAtrial Septal Defect (ASD)Atrioventricular Nodal Reentrant Tachycardia (AVNRT)Bicuspid Aortic ValveBlood ClotsCardiac ArrestCardiomyopathyCerebral HypoxiaCirrhosisCornelia De Lange SyndromeDextrocardiaDextrocardia with Situs InversusDiGeorge SyndromeDouble Aortic ArchDouble DiscordiaEbstein's AnomalyEndocarditisErythropoietic ProtoporphyriaHeart BlockHeart FailureHypertensionHypoparathyroidismHypothermiaImmune Defect due to Absence of ThymusLactic AcidosisMarfan SyndromeMitral AtresiaMitral Valve RegurgitationPacemaker ImplantationPatent Ductus ArteriosusPediatric MyocarditisPleural EffusionPorphyriaProtoporphyriaPulmonary Atresia with Ventricular Septal DefectSinus of Valsalva AneurysmSitus InversusSubpulmonary StenosisSubvalvular Aortic StenosisSupravalvular Aortic StenosisSVC ObstructionThoracic Aortic AneurysmTracheobronchomalaciaTricuspid RegurgitationVascular Ring

Publications

5 total
Discordances in Kinetic Energy Between the Superior Cavopulmonary Connection and Single Ventricle Are Associated With Suboptimal Fontan Outcomes: A Pre-Fontan 4-Dimensional Flow Study.

Journal of the American Heart Association • April 03, 2025

Jacqueline Contento, Mithra Agamy, Maren Brinken, Ryan O'hara, Nicholas Mouzakis, Janet Kruetzer, Rittal Mehta, Roland Axt Fliedner, Elias Balaras, Francesco Capuano, Ravi Vegulla, Yves D'udekem, Yue-hin Loke

Background: Patients with functional single ventricle (SV) are at risk for adverse outcomes after staged palliation from the superior cavopulmonary connection (SCPC) to the Fontan. Current pre-Fontan assessment by cardiac magnetic resonance and cardiac catheterization includes measuring atrioventricular valve regurgitation, aortopulmonary collateral burden, and pressures. Four-dimensional flow can quantify complex flows representing hemodynamic inefficiency. This study determined the clinical significance of kinetic energy (KE) and viscous energy loss in patients before the Fontan procedure using 4-dimensional flow. Results: This was a retrospective analysis of patients before the Fontan procedure who underwent ferumoxytol-enhanced cardiac magnetic resonance and same-day catheterization. Four-dimensional flow data sets were analyzed using ITFlow (CardioFlowDesign) to measure KE/viscous energy loss in the atrium, SV, and SCPC. A composite outcome was defined by rejected Fontan candidacy, prolonged hospitalization, lymphatic dysfunction, or heart failure. The relationship between these outcomes and KE/viscous energy loss was assessed by bivariable and multivariable logistic regression analyses as appropriate. Sixty-five patients (3.9±1.5 years, 0.64±0.1 m2) were included. Fifty (77%) proceeded to Fontan operation with median hospitalization time of 8.5 (interquartile range, 7-12.7) days. Twenty-six (40%) experienced a composite outcome, including 9 with rejected candidacy. Lower SCPC flow was associated with an outcome (P=0.042). Meanwhile, higher SV KE and lower SCPC KE were independently associated with composite outcome (odds ratio, 3.63 [95% CI, 1.32-13.2]; P=0.0263; odds ratio, 0.906 [95% CI, 0.814-0.980]; P=0.0377). Higher SV KE and lower SCPC KE corresponded to significant atrioventricular valve regurgitation, higher aortopulmonary collateral burden, and higher cathetherization pressures. Conclusions: Four-dimensional flow analysis provides insight into SV hemodynamics and is associated with short-term outcomes. Future work will analyze the longitudinal implications for patients undergoing the Fontan procedure.

Hemostatic Outcome Definitions in Pediatric Extracorporeal Membrane Oxygenation: Challenges in Cohorts From Rotterdam (2019-2023) and Melbourne (2016-2022).

Pediatric Critical Care Medicine : A Journal Of The Society Of Critical Care Medicine And The World Federation Of Pediatric Intensive And Critical Care Societies • March 06, 2025

Joppe Drop, Suelyn Van Den Helm, Natasha Letunica, Enno Wildschut, Matthijs De Hoog, Willem De Boode, Rebecca Barton, Hui Yaw, Fiona Newall, Stephen Horton, Roberto Chiletti, Amy Johansen, Derek Best, Joanne Mckittrick, Warwick Butt, Yves D'udekem, Graeme Maclaren, Vera Ignjatovic, Chantal Attard, C Van Ommen, Paul Monagle

Objectives: To determine if a priori standardization of outcome hemostatic definitions alone was adequate to enable useful comparison between two cohorts of pediatric extracorporeal membrane oxygenation (ECMO) patients, managed according to local practice and protocol. Design: Comparison of two separate prospective cohort studies performed at different centers with standardized outcome definitions agreed upon a priori. Setting: General and cardiac PICUs at the Royal Children's Hospital (RCH) in Melbourne, Australia, and the Sophia Children's Hospital (SCH) in Rotterdam, The Netherlands. Patients: Children (0-18 yr old) undergoing ECMO. Interventions: None. Measurements and main Results: Although outcome definitions were standardized a priori, the interpretation of surgical interventions varied. The SCH study included 47 ECMO runs (September 2019 to April 2023), and the RCH study included 97 ECMO runs (September 2016 to Jan 2022). Significant differences in patient populations were noted. RCH patients biased toward frequent cardiac ECMO indications, central cannulation, and cardiopulmonary bypass before ECMO. The frequency of outcome ascertainment was not standardized. Conclusions: This international comparison shows that standardizing hemostatic outcome definitions alone is insufficient for sensible comparison. Uniform interpretation of definitions, consistent frequency of outcome ascertainment, and stratification based on patient populations and ECMO practices are required. Our results highlight the granularity of detail needed for cross-center comparison of hemostatic outcomes in pediatric ECMO. Further work is needed as we move toward potential multicenter trials of pediatric ECMO.

Rehabilitation Strategy Should Not Be a Pretext for Suboptimal Repair for Pulmonary Atresia, Ventricular Septal Defect, and Major Aortopulmonary Collateral Arteries.

World Journal For Pediatric & Congenital Heart Surgery • February 21, 2025

Manan Desai, Aybala Tongut, Yves D'udekem

Pulmonary atresia, ventricular septal defect, and major aortopulmonary collaterals are a challenging congenital anomaly to manage surgically with different centers and strategies producing wide-ranging outcomes. Over the past few decades despite diverging treatment pathways, there is an emerging consensus of how these patients "should" be treated. Quite often a combination of rehabilitation strategy and a unifocalization approach has to be tailored to each patient to address the anatomic and physiological variations that characterize this congenital heart defect. Irrespective of the surgical approach, the goal should be to have a complete repair with acceptable right heart pressure ensuring survival and a good quality of life.

Neurodevelopmental Outcomes After Nitric Oxide During Cardiopulmonary Bypass for Open Heart Surgery: A Randomized Clinical Trial.

JAMA Network Open • February 05, 2025

Debbie Long, Kristen Gibbons, Stephen Horton, Kerry Johnson, David H Buckley, Simon Erickson, Marino Festa, Yves D'udekem, Nelson Alphonso, Renate Le Marsney, David Winlaw, Kate Masterson, Kim Van Loon, Paul Young, Andreas Schibler, Luregn Schlapbach, Warwick Butt

Children with congenital heart defects who undergo cardiopulmonary bypass (CPB) surgery are at risk for delayed or impaired neurodevelopmental outcomes. Nitric oxide (NO) added to the CPB oxygenator may reduce systemic inflammation due to CPB and improve recovery from surgery, including improved neurodevelopmental outcomes. To investigate neurodevelopment, health-related quality of life (HRQOL), and factors associated with impaired neurodevelopment at 12 months post surgery in infants who received CPB with NO or standard CPB. This double-masked randomized clinical trial was conducted in 6 centers in Australia, New Zealand, and the Netherlands between July 19, 2017, and April 28, 2021, with a preplanned prospective follow-up 12 months postrandomization completed on August 5, 2022. The cohort included 1364 infants younger than 2 years who underwent open heart surgery with CPB for congenital heart disease. The intervention group received NO 20 ppm into the CPB oxygenator. The control group received standard CPB. The primary outcome was neurodevelopment, defined as the Ages and Stages Questionnaire, Third Edition (ASQ-3) total score. Secondary outcomes were HRQOL and functional status as measured by Pediatric Quality of Life Inventory and modified Pediatric Overall Performance Category scores, respectively. Sensitivity analyses modeled the outcome for patients lost to follow-up. Of 1318 infants alive 12 months after randomization, follow-up was performed in 927, with 462 patients in the NO group and 465 in the standard care group (median [IQR] age at follow-up, 16.6 [13.7-19.8] months; median [IQR] time since randomization, 12.7 [12.1-13.9] months; 516 male [55.7%]). There were no differences between the NO and standard care groups in ASQ-3 total score (mean [SD], 196.6 [75.4] vs 198.7 [73.8], respectively; adjusted mean difference, -2.24; 95% CI, -11.84 to 7.36). There were no differences in secondary outcomes. Prematurity (gestational age <37 weeks), univentricular lesions, congenital syndromes, and longer intensive care unit length of stay were associated with lower ASQ-3 total scores in adjusted multivariable analyses. In this randomized clinical trial of infants with congenital heart disease, NO administered via the CPB oxygenator did not improve neurodevelopmental outcomes or HRQOL 12 months after open heart surgery. Further research should explore homogenous cohorts with higher surgical risk and higher-dose or alternative therapies. ANZCTR Identifier: ACTRN12617000821392.

Wellbeing and quality of life among parents of individuals with Fontan physiology.

Quality Of Life Research : An International Journal Of Quality Of Life Aspects Of Treatment, Care And Rehabilitation • January 03, 2025

Kate Marshall, Yves D'udekem, David Winlaw, Diana Zannino, David Celermajer, Karen Eagleson, Ajay Iyengar, Dominica Zentner, Rachael Cordina, Gary Sholler, Susan Woolfenden, Nadine Kasparian

Objective: To examine global and health-related quality of life (QOL) among parents of individuals with Fontan physiology and determine associations with sociodemographic, parent and child-related health, psychological, and relational factors. Methods: Parents participating in the Australian and New Zealand Fontan Registry (ANZFR) QOL Study (N = 151, Parent Mean age = 47.9 ± 10.2 years, age range: 31.6-79.6 years, 66% women; child Mean age = 16.3 ± 8.8, age range: 6.9-48.7 years, 40% female) completed a series of validated measures. Health-related QOL was assessed using the PedsQL 4.0 Core Generic Scales for adults and global QOL was assessed using a visual analogue scale (0-10). Results: Most parents (81%) reported good global QOL (≥ 6), consistent with broader population trends. Nearly one-third of parents (28%) reported at-risk health-related QOL (based on total PedsQL scores) with physical functioning most affected (44%). Psychological factors, including psychological stress and sense of coherence, emerged as the strongest correlates of global and health-related QOL, explaining an additional 16 to 30% of the variance (using marginal R2). Final models explained 35 and 57% and of the variance in global and health-related QOL, respectively (marginal R2). Relational factors, including perceived social support and family functioning contributed minimally when analyzed alongside psychological variables. Conclusions: While parents of individuals with Fontan physiology report good global QOL, challenges in health-related QOL exist. We identified key psychological, sociodemographic, and health-related factors associated with parental QOL outcomes. These data may aid early identification of physical and psychosocial difficulties and guide targeted health resource allocation for this population.

Clinical Trials

1 total

Tetralogy of Fallot for Life

Completed

The aim is to conduct a prospective multi-centre international inception cohort study with an enrollment goal of 3,000 TOF patients and 2 year follow-up post-repair. The proposed sample size and methodology will result in statistically powerful results to allow for evidence-based change to current TOF surgical practices.

Participants: 1108

Frequently Asked Questions

What services do you offer as a pediatric cardiologist?
I provide care for a range of congenital and pediatric heart conditions, including heart valve issues, congenital heart defects like ASD, VSD, and complex problems such as HLHS, transposition and truncus. I also offer procedures like heart valve repair when appropriate.
Which conditions do you treat in children and babies?
I treat congenital heart disease and related conditions in infants, children and adolescents, including arrhythmias, heart failure when it arises, vascular and valve problems, and rare congenital vascular issues.
How can I book an appointment?
Appointments are arranged through the Parkville clinic. Please contact the clinic to check availability and referral requirements, and I’ll review your child’s history and arrange appropriate tests or consultations.
Where is your clinic located?
The practice is on Flemington Road, Parkville, VIC 3052, Australia.
Do you perform heart valve repair or other surgical interventions?
Yes. I have experience with heart valve repair and other surgical and post-surgical care related to congenital heart disease.
How many years of experience do you have?
I have about 38 years of experience in cardiology and pediatric cardiac surgery.
What kinds of problems might require long-term follow-up for my child?
Children with congenital heart disease or significant heart conditions often need ongoing follow-up to monitor heart function, growth, and any late complications after treatment.